S'abonner

Effect of the number of lymph nodes harvested on the long-term survival of gastric cancer patients according to tumor stage and location: a 12-year study of 1,637 cases - 14/08/15

Doi : 10.1016/j.amjsurg.2015.01.029 
Zhanlong Shen, M.D., Ph.D. , Yingjiang Ye, M.D., Ph.D., Qiwei Xie, M.M., Bin Liang, M.D., Ph.D., Kewei Jiang, M.D., Ph.D., Shan Wang, M.D., Ph.D.
 Department of Gastroenterological Surgery, Peking University People’s Hospital, Beijing 100044, P.R. China 

Corresponding author. Tel./fax: +86-10-88326600.

Abstract

Background

The effect of the number of lymph nodes harvested on the long-term survival of gastric cancer according to Tumor, Node, and Metastasis (TNM) stage and tumor location remains unclear.

Methods

Patients who underwent gastrectomy for gastric cancer (1998 to 2009) were evaluated retrospectively (1,637 patients). The patients’ clinicopathological variables, overall survival (OS), and progression-free survival (PFS) were recorded. The effect of the number of lymph nodes harvested on survival was analyzed according to TNM stage and tumor location.

Results

Harvest of greater than 30 lymph nodes was associated with significantly better OS and PFS than less than or equal to 14 lymph nodes, but no significant difference was observed between less than or equal to 14 and 15 to 29 lymph nodes harvested. The number of lymph nodes harvested was significantly associated with the OS or/and PFS of late stage cancer (N+, T3 to T4, and stage III to IV), harvest of greater than 30 lymph nodes brought significantly better survival compared with the other 2 groups. A higher number of harvested lymph nodes was associated with significantly better PFS for gastric cancer of the body of stomach, but not for proximal, distal, and whole stomach cancer. When the tumor was located in the body of the stomach, the PFS was better with 15 to 29 lymph nodes than less than 14 lymph nodes; however, the OS and PFS were not significantly different between greater than 30 lymph nodes and 15 to 29 lymph nodes. TNM stage and number of lymph nodes harvested were the independent risk factors affecting the survival.

Conclusion

Tailored lymphadenectomy according to TNM stage and tumor location might be considered for gastric cancer patients.

Le texte complet de cet article est disponible en PDF.

Highlights

The effect of the number of lymph nodes harvested on the long-term survival of gastric cancer patients according to TNM stage and tumor location remains unclear.
Harvest of >30 lymph nodes was associated with significantly better OS and PFS than ≤14 lymph nodes.
The number of lymph nodes harvested was significantly associated with the OS or/and PFS of late stage cancer (N+, T3–T4 and stage III–IV).
A higher number of harvested lymph nodes was associated with significantly better PFS for gastric cancer of the body of stomach.
Tailored lymphadenectomy according to TNM stage and tumor location might be considered for gastric cancer patients.

Le texte complet de cet article est disponible en PDF.

Keywords : Gastric cancer, Survival, Lymph node harvest, TNM stage, Tumor location


Plan


 Supported by the National Science Foundation of China (81372290, 81372291) and Peking University People’s Hospital Research and Development Funds (RDB 2012-18, RDB 2013-15).
 The authors declare no conflicts of interest.


© 2015  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 210 - N° 3

P. 431 - septembre 2015 Retour au numéro
Article précédent Article précédent
  • Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis
  • Jennifer Y. Lam, Yarrow J. McConnell, Justin D. Rivard, Walley J. Temple, Lloyd A. Mack
| Article suivant Article suivant
  • Does lymph node ratio affect prognosis in gastroesophageal cancer?
  • Marcovalerio Melis, Antonio Masi, Antonio Pinna, Steven Cohen, Ioannis Hatzaras, Russell Berman, Leon H. Pachter, Elliot Newman

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.